Literature DB >> 12852510

Clinical characteristics and outcomes of surgical patients with vancomycin-resistant enterococcal infections.

Charles S Joels1, Brent D Matthews, Lee B Sigmon, Reem Hasan, Charles E Lohr, Kent W Kercher, James Norton, Ronald F Sing, B Todd Heniford.   

Abstract

The purpose of this study is to determine risk factors associated with mortality in surgical patients with vancomycin-resistant enterococcus (VRE) infections. The hospitalizations of surgical patients with VRE infections from January 1998 to December 2001 were reviewed. Statistical analysis was performed using the Student's t test, chi square, and Fisher's exact test. Thirty-one surgical patients (male:female, 14:17) with a mean age of 51.9 years (range, 21-83 years) developed VRE infection. Infections included bacteremia (12), urinary tract (11), surgical site (seven), and soft tissue (five) infections and intra-abdominal abscess (one). Nine (29.0 per cent) patients received recent outpatient antibiotics and 20 (64.5 per cent) were on steroids. Fifteen (48.4 per cent) patients were treated with intravenous vancomycin before infection. Twelve (38.1 per cent) patients died with a trend toward advanced age (60.7 vs 46.5 years; P = 0.06). The incidence of VRE infection in kidney transplant patients was 1.8 per cent. Six transplant patients (five kidney and one kidney/ pancreas) developed VRE infections with four deaths. Hypertension (P = 0.04), coronary artery disease (P = 0.02), and the need for intra-arterial pressure monitoring (P = 0.04) were associated with mortality. Isolate location, gender, diabetes, renal dysfunction, respiratory disease, liver disease, and serum albumin were not associated with mortality. Kidney transplant patients have a high incidence of VRE infection. Surgical patients with VRE infections have a high mortality rate. Hypertension and coronary artery disease are risk factors for mortality.

Entities:  

Mesh:

Year:  2003        PMID: 12852510

Source DB:  PubMed          Journal:  Am Surg        ISSN: 0003-1348            Impact factor:   0.688


  6 in total

1.  Surgical site infections in a tertiary health care center: prospective cohort study.

Authors:  Vesna Suljagić; Miodrag Jevtic; Boban Djordjevic; Aleksandra Jovelic
Journal:  Surg Today       Date:  2010-07-30       Impact factor: 2.549

2.  A Vaccine Approach for the Prevention of Infections by Multidrug-resistant Enterococcus faecium.

Authors:  Srinivas Kodali; Evgeny Vinogradov; Fiona Lin; Nancy Khoury; Li Hao; Vilo Pavliak; C Hal Jones; Diana Laverde; Johannes Huebner; Kathrin U Jansen; Annaliesa S Anderson; Robert G K Donald
Journal:  J Biol Chem       Date:  2015-06-24       Impact factor: 5.157

3.  Peptide nucleic acid fluorescent in situ hybridization for hospital-acquired enterococcal bacteremia: delivering earlier effective antimicrobial therapy.

Authors:  Graeme N Forrest; Mary-Claire Roghmann; Latoya S Toombs; Jennifer K Johnson; Elizabeth Weekes; Durry P Lincalis; Richard A Venezia
Journal:  Antimicrob Agents Chemother       Date:  2008-07-28       Impact factor: 5.191

4.  In vivo efficacy and pharmacokinetics of AC98-6446, a novel cyclic glycopeptide, in experimental infection models.

Authors:  William J Weiss; Timothy Murphy; Eileen Lenoy; Mairead Young
Journal:  Antimicrob Agents Chemother       Date:  2004-05       Impact factor: 5.191

5.  Systemic inflammatory response syndrome in adult patients with nosocomial bloodstream infections due to enterococci.

Authors:  Katharine Bar; Hilmar Wisplinghoff; Richard P Wenzel; Gonzalo M L Bearman; Michael B Edmond
Journal:  BMC Infect Dis       Date:  2006-09-26       Impact factor: 3.090

6.  Prevalence and risk factors for VRE colonisation in a tertiary hospital in Melbourne, Australia: a cross sectional study.

Authors:  Surendra Karki; Leanne Houston; Gillian Land; Pauline Bass; Rosaleen Kehoe; Sue Borrell; Kerrie Watson; Denis Spelman; Jacqueline Kennon; Glenys Harrington; Allen C Cheng
Journal:  Antimicrob Resist Infect Control       Date:  2012-10-08       Impact factor: 4.887

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.